share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/10/24 21:18

Moomoo AI 已提取核心訊息

BioVie announced a registered direct offering of 2,667,000 common shares priced at $2.25 per share, aiming to raise approximately $6 million in gross proceeds. The offering, expected to close on October 24, 2024, is being conducted at-the-market under Nasdaq rules with ThinkEquity acting as the sole placement agent.In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,667,000 shares at an exercise price of $2.12 per share. These warrants will become exercisable six months from issuance and expire five years after the initial exercise date. Additionally, the placement agent received warrants to purchase 133,350 shares at $2.8125 per share.The company plans to use the net proceeds for working capital and general corporate purposes. The shares offering was made under BioVie's effective S-3 registration statement, while the warrants were offered through a private placement exempt from registration requirements under Securities Act Section 4(a)(2).
BioVie announced a registered direct offering of 2,667,000 common shares priced at $2.25 per share, aiming to raise approximately $6 million in gross proceeds. The offering, expected to close on October 24, 2024, is being conducted at-the-market under Nasdaq rules with ThinkEquity acting as the sole placement agent.In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,667,000 shares at an exercise price of $2.12 per share. These warrants will become exercisable six months from issuance and expire five years after the initial exercise date. Additionally, the placement agent received warrants to purchase 133,350 shares at $2.8125 per share.The company plans to use the net proceeds for working capital and general corporate purposes. The shares offering was made under BioVie's effective S-3 registration statement, while the warrants were offered through a private placement exempt from registration requirements under Securities Act Section 4(a)(2).
BioVie公司宣佈以每股2.25美元的價格發行2,667,000股普通股，計劃募集約600萬美元的總收益。該發行預計將於2024年10月24日完成，按照納斯達克規則進行市場發行，ThinkEquity擔任唯一的安置代理。在一項同時進行的定向增發中，公司將發行未註冊的Warrants，允許購買最多2,667,000股，行使價格爲每股2.12美元。這些Warrants將在發行六個月後生效，並在初始行使日期後的五年內到期。此外，安置代理還獲得了以每股2.8125美元購買133,350股的Warrants。公司計劃將淨收益用於營運資金和一般企業用途。股份發行是在BioVie有效的S-3註冊聲明下進行的，而Warrants是通過免於註冊要求的定向增發根據《證券法》第4(a)(2)節進行的。
BioVie公司宣佈以每股2.25美元的價格發行2,667,000股普通股，計劃募集約600萬美元的總收益。該發行預計將於2024年10月24日完成，按照納斯達克規則進行市場發行，ThinkEquity擔任唯一的安置代理。在一項同時進行的定向增發中，公司將發行未註冊的Warrants，允許購買最多2,667,000股，行使價格爲每股2.12美元。這些Warrants將在發行六個月後生效，並在初始行使日期後的五年內到期。此外，安置代理還獲得了以每股2.8125美元購買133,350股的Warrants。公司計劃將淨收益用於營運資金和一般企業用途。股份發行是在BioVie有效的S-3註冊聲明下進行的，而Warrants是通過免於註冊要求的定向增發根據《證券法》第4(a)(2)節進行的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Plus Therapeutics
    PSTV
    -- 1.4400
    AEON Biopharma
    AEON
    -- 0.710
    Tonix Pharmaceuticals
    TNXP
    -- 14.6300
    ALX Oncology
    ALXO
    -- 1.310
    Alto Neuroscience
    ANRO
    -- 3.950
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！